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Background: 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (IspF) catalyzes the conversion of
4-diphosphocytidyl-2C-methyl-D-erythritol-2-phosphate to 2C-methyl-D-erythritol-2,4-cyclodiphosphate and
cytidine monophosphate in production of isoprenoid-precursors via the methylerythritol phosphate biosynthetic
pathway. IspF is found in the protozoan Plasmodium falciparum, a parasite that causes cerebral malaria, as well as in
many Gram-negative bacteria such as Burkholderia cenocepacia. IspF represents a potential target for development of
broad-spectrum antimicrobial drugs since it is proven or inferred as essential in these pathogens and absent from
mammals. Structural studies of IspF from these two important yet distinct pathogens, and comparisons with
orthologues have been carried out to generate reagents, to support and inform a structure-based approach to
early stage drug discovery.
Results: Efficient recombinant protein production and crystallization protocols were developed, and high-resolution
crystal structures of IspF from P. falciparum (PfIspF) and B. cenocepacia (BcIspF) in complex with cytidine nucleotides
determined. Comparisons with orthologues, indicate a high degree of order and conservation in parts of the active site
where Zn2+ is bound and where recognition of the cytidine moiety of substrate occurs. However, conformational flexibility
is noted in that area of the active site responsible for binding the methylerythritol component of substrate. Unexpectedly,
one structure of BcIspF revealed two molecules of cytidine monophosphate in the active site, and another identified citrate
coordinating to the catalytic Zn2+. In both cases interactions with ligands appear to help order a flexible loop at one side of
the active site. Difficulties were encountered when attempting to derive complex structures with other ligands.
Conclusions: High-resolution crystal structures of IspF from two important human pathogens have been obtained and
compared to orthologues. The studies reveal new data on ligand binding, with citrate coordinating to the active site Zn2+
and when present in high concentrations cytidine monophosphate displays two binding modes in the active site. Ligand
binding appears to order a part of the active site involved in substrate recognition. The high degree of structural
conservation in and around the IspF active site suggests that any structural model might be suitable to support a program
of structure-based drug discovery.
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Isoprenoids contribute to a myriad of essential biological
functions, for example as the prenyl groups that anchor
proteins to membranes, as components of respiratory
membranes, enzyme cofactors, and as scaffolds for the as-
sembly of glycan structures [1-4]. Two distinct biosyn-
thetic routes supply the universal isoprenoid-precursors
isopentenyl pyrophosphate and dimethylallyl pyrophosphate.
The mevalonate (MVA) pathway is present in animals, fungi
and archaea while the 2C-methyl-D-erythritol-4-phosphate
(MEP) pathway is widely distributed in bacteria, algae and
several apicomplexan parasites, including Plasmodium
species responsible for malaria [5,6]. Both MVA and
MEP pathways occur in plants; the former operates in the
cytoplasm and the latter in chloroplasts [7]. In most api-
complexan parasites the components of the MEP pathway
are localized to an organelle known as the apicoplast, a
relict chloroplast, which is also responsible for additional
biosynthetic processes [8]. The organelle, which resembles
a cyanobacterium is thought to have been acquired from
an ancestral endosymbiotic event with an alga. All MEP
pathway enzymes in P. falciparum are synthesized in the
cytoplasm but they carry an apicoplast targeting sequence,
which then drives localization [8]. The disruption of api-
coplast replication results in parasites that are isopentenyl
pyrophosphate auxotrophs [9].
Part of the interest in the MEP pathway concerns anti-
microbial drug research and several observations sup-
port the idea that the pathway contains potential drug
targets, enzymes whose inhibition may provide broad-Figure 1 Reaction catalyzed by IspF. A catalytic Zn2+ aligns and polarize
to produce MEcPP and CMP.spectrum antimicrobial activity [5,6]. We identified the
Zn2+-dependent 2C-methyl-D-erythritol-2,4-cyclodiphosphate
synthase [EC: 4.6.1.12] the fifth enzyme in the pathway as a
target of interest. This enzyme, also known as IspF,
catalyzes the conversion of 4-diphosphocytidyl-2C-methyl-
D-erythritol-2-phosphate (CDP-MEP) to 2C-methyl-D-
erythritol-2,4-cyclodiphosphate (MEcPP) and cytidine
monophosphate (CMP, Figure 1). We considered a di-
verse set of criteria that have been established as key
with respect to target assessment for early stage anti-
microbial drug discovery [10]. These criteria include
genetic and chemical validation of the target, and the
availability of accurate structural information and appro-
priate reagents to guide the development of structure-
activity relationships. Three primary factors were taken
into consideration. First, genetic methods have identified
that individual components of the pathway, including IspF
are essential for bacterial survival. For example, the essen-
tiality of the ispF gene for growth and survival of Bacillus
subtilis, Escherichia coli and Mycobacterium tuberculosis
is established [11-15]. Secondly, this pathway is absent
from humans [5,6] potentially mitigating against toxicity
issues. Thirdly, chemical validation of the pathway is
provided by the antibacterial fosmidomycin, a potent
inhibitor of 1-deoxy-D-xylulose 5-phosphate reduc-
toisomerase, an enzyme that contributes to an early
stage in the pathway. This last point regarding valid-
ation is reinforced by further work, which shows that
fosmidomycin and derivatives are also efficacious in
killing P. falciparum [16-18].s the β-phosphate to support nucleophilic attack by the 2-phosphate
Table 1 Crystallographic statistics for Pf IspF
Structure/PDB Pf IspF:CDP/4C81 Unliganded
Pf IspF/4C82
Space group H3 H3
Unit cell dimensions
a, b, c (Å) 84.9, 84.9, 101.0 84.2, 84.2, 102.5
Resolution rangea (Å) 41.63-1.60 (1.69-1.60) 29.71-2.00 (2.11-2.00)
No. reflections 181781 (16968) 41802 (5780)
Unique reflections 35607 (5194) 18068 (2622)
Completeness (%) 99.4 (99.3) 98.6 (97.0)
Rmerge
b (%) 9.3 (42.0) 9.4 (48.2)
Multiplicity 5.1 (3.3) 2.3 (2.2)
< I/σ(I)> 11.1 (2.6) 5.3 (2.0)
Wilson B (Å2) 24.4 32.0
Rwork
c/Rfree
d (%) 14.4, 16.5 19.4, 22.6
Number of residues/
waters/ligands
156, 85 waters, 1 CDP,
2 Zn2+, 3 Cl-, 1 SO4
2-
156, 94 waters,





Bond angles (º) 1.000 2.087
Mean B-factors (Å2)
Overall 22.9 37.6
Main chain, side chain 25.1, 33.8 34.2, 39.5
Waters 35.2 47.8
Ligands 34.9, 28.3 (0.6, 0.4 CDP) 44.5 (Zn2+, SO4
2-)
35.8 (Zn2+, Cl-, SO4
2-)
Ramachandran plot
Favoured regions (%) 98.6 95.3
Allowed regions (%) 0.7 4.0
Outliers 1 outlier: Asp79 1 outlier: Asp79
aValues in parentheses refer to the highest resolution shell. bRmerge = ∑ hkl ∑ i|Ii
(hkl) − < I(hkl) > |/∑hkl ∑ iIi(hkl); where Ii(hkl) is the intensity of the ith
measurement of reflection hkl and < I(hkl) > is the mean value of Ii(hkl) for all i
measurements. cRwork = ∑ hkl‖Fo| ‐ |Fc‖/∑|Fo|, where Fo is the observed structure
factor and Fc is the calculated structure factor.
dRfree is the same as Rwork
except calculated with a subset, 5%, of data that are excluded from the
refinement calculations.
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IspF structure, specificity, and mechanism [19-22]. The
structure of IspF has been derived from a dozen species in
addition to the two new ones disclosed in this publication.
More recently new IspF ligands including potent inhibi-
tors have been identified [23-25], some of which have also
been shown to inhibit the growth of P. falciparum within
infected erythrocytes with respectable IC50 values of 1.4-
1.6 μM [26]. These approaches have been complemented
by NMR-based fragment screening and co-crystallization
efforts targeting IspF from B. pseudomallei (BpIspF) [27].
Aims
We sought to further inform the assessment of IspF as a
drug target with crystallographic studies of the enzyme
from two serious human pathogens, the Gram-negative
bacterium Burkholderia cenocepacia (BcIspF) and the
parasitic protozoan Plasmodium falciparum (Pf IspF).
Results and discussion
The structure of IspF
Efficient recombinant protein production systems, purifi-
cation protocols and reproducible crystallization condi-
tions have been established for BcIspF and Pf IspF leading
to yields of up to 25 mg L-1 and 2.5 mg L-1of E. coli cul-
ture respectively. High-resolution crystal structures of
BcIspF in complex with CMP or citrate, and of Pf IspF in
complex with CDP, as well as an unliganded Pf IspF struc-
ture have been determined. Crystallographic statistics are
presented in Tables 1 and 2.
The calculated masses of the BcIspF and Pf IspF sub-
units are 19.3 kDa and 20.5 kDa respectively and the
polypeptide folds into a single α/β domain that consists
of a four-stranded mixed β-sheet on one side with three
α-helices on the other (Figure 2). IspF forms a stable
homotrimer as observed in size-exclusion chromatog-
raphy, which returns an estimate of 60 kDa for each. In
all IspF crystal structures three subunits form a compact
bell-shaped assembly approximately 45 Å by 60 Å in the
axial and equatorial dimensions respectively (Figure 2).
A surface area approximately equivalent to that of one
subunit is buried on oligomerization. The accessible sur-
face area (ASA) of an IspF monomer averages out as ap-
proximately 8130 Å2 for BcIspF and 8680 Å2 for Pf IspF.
The ASA for the BcIspF trimer is 16080 Å2, and for the
Pf IspF trimer 18180 Å2. In the case of BcIspF the asym-
metric unit consists of three subunits, chains A, B, C,
which are related by three-fold non-crystallographic
symmetry (NCS). NCS is high with least squares over-
lays of 161Cα positions in the range 0.2 - 0.3 Å. One
subunit is present in the asymmetric unit of Pf IspF
and the trimer is generated by the symmetry opera-
tions (−x + y, -x, z) and (−y, x-y, z). A least squares
superimposition of Cα positions from both Pf IspFstructures matches all 156 residues with an RMSD of
0.3 Å. Since there are no pronounced differences between
the CDP bound and unliganded Pf IspF structures only
the former is discussed.
Structural comparisons of IspF orthologues from the
Protein Data Bank (PDB) were carried out using the
DALI server [28]. Pairwise sequence identities range
from 28 to 90%, Z scores from 18 to 31 and RMSD
values from 0.3 to 2.5 Å. The apicoplast targeting se-
quence of Plasmodium spp. and the chloroplast target-
ing sequence of Arabidopsis thaliana IspF were excluded
in the calculation of sequence identities. Using representa-
tive IspF structures from each of the twelve unique organ-
isms in the PDB, an average RMSD of Cα positions was
Table 2 Crystallographic statistics for BcIspF
Structure/PDB BcIspF:CMP/4C8G BcIspF:2CMP/4C8E BcIspF:citrate/4C8I
Space group C2 C2 C2
Unit cell dimensions
a, b, c (Å), 97.2, 88.6, 72.4, 97.9, 89.3, 73.0, 131.7, 52.5, 72.1,
β 103.9° 104.2° 94.6°
Resolution range (Å) 29.84-2.00 (2.10-2.00) 19.32-1.90 (2.00-1.90) 40.90-2.00 (2.10-2.00)
No. reflections 98451 (13335) 164120 (24760) 119715 (15957)
Unique reflections 38409 (5579) 47918 (6972) 33460 (4696)
Completeness (%) 96.0 (95.4) 99.9 (100.0) 99.4 (96.1)
Rmerge (%) 11.0 (32.2) 13.8 (32.3) 3.2 (7.8)
Multiplicity 2.6 (2.4) 3.4 (3.6) 3.6 (3.4)
< I/σ(I)> 5.9 (2.7) 6.2 (3.1) 23.9 (12.8)
Wilson B (Å2) 16.5 16.3 18.7
Rwork/Rfree (%) 23.7, 28.0 20.4, 25.1 15.6, 19.8
Number of residues 458, 173 waters, 483, 420 waters, 460, 320 waters,
Waters/ligands 3 CMP, 3 Zn2+, 1 Mg2+, 1 PO4
3- 6 CMP, 3 Zn2+, 1 SO4
2- 3 citrates,3 Zn2+, 1 PO4
3-
1di(hydroxyethyl)ether
RMSD bond lengths (Å)/ 0.020 0.011 0.020
bond angles (º) 2.198 1.526 2.101
Mean B-factors (Å2)
Overall 14.5 17.2 18.9
Main chain, side chain 13.6, 15.3 18.7, 20.4 16.2, 20.1
Waters 16.5 29.9 26.7
Ligands 15.1 (CMP) 24.8 (Zn2+, Mg2+, PO4
3-) 18.2 (CMP 1) 23.4, 36.8, 43.1 (citrates)




Favoured regions (%) 96.9 97.8 97.7
Allowed regions (%) 2.2 2.2 2.3
Outliers 4 outliers: Ser37A/C, Tyr29B, Gly17C
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RMSD was 1.5 Å and therefore the comparisons are indi-
cative of an enzyme that has a highly conserved structure.
The two IspF variants studied here, with sequence
identity of 38%, a DALI Z score 23 and RMSD value typ-
ically around 1.7 Å, can be taken to represent a compari-
son of structures that are amongst the most divergent. A
structure-based sequence alignment of BcIspF with
Pf IspF is shown in Figure 3 and this, together with com-
parisons based on consideration of 854 IspF sequences,
provides a context in which to discuss key features.
Pf IspF contains a 19 residue insertion at the N-terminus,
Lys76 - Glu94, immediately after β1 that does not
align with bacterial IspF sequences. Here, residues
Tyr82 - Phe97 could not be modeled due to the lack of
ordered electron density (Figure 2c).The most similar structures of each new IspF structure
were noted. BcIspF aligns 151 residues with an RMSD of
0.4 Å to BpIspF (Z = 31, 90% sequence identity). Pf IspF
aligns 143Cα positions with an RMSD of 0.8 Å, and 151
residues with an RMSD of 1.2 Å with subunits of the en-
zyme from P. vivax (PvIspF, Z = 25, 66% sequence iden-
tity) and A. thaliana (AtIspF, Z = 25, 42% sequence
identity) respectively. The PvIspF structure at 2.3 Å
resolution was deposited in the PDB without an associ-
ated publication [PDB: 3B6N]. Although Zn2+ has been
modeled at the active site (discussed below), the corre-
sponding B-factor of 119 Å2 is 2.6 times greater than the
average B-factor of the protein atoms, 46 Å2, and the
side chain of a coordinating histidine, His170, is poorly
oriented. We conclude that a water molecule may be a
more likely occupant of this metal binding site. In
Figure 2 Overall structure of IspF. IspF forms a homotrimer. a) Axial view. b) Side view. The figure has been drawn using the coordinates for
Pf IspF in complex with CDP; a trimer has been generated from symmetry-related subunits. Subunits (displayed as ribbons) are colored blue, orange
and green respectively. Zn2+ cations are displayed as grey spheres, sulfate and CDP are displayed as sticks. The secondary structure of Pf IspF and BcIspF
subunits is shown in c) and d) respectively, similarly orientated. The location of missing loops is highlighted with arrows.
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at 1.60 Å resolution, the B-value for Zn2+ of 20 Å2 is
lower than the average B-factor over all the protein
atoms of 29 Å2.
The enzyme active site is located in a cleft at the inter-
face of two subunits (Figure 2a) and here Zn2+ is coordi-
nated by the side chains of two histidines and an
aspartate [19]. The coordinating residues are Asp10,
His12 and His44 in BcIspF, Asp71, His73 and His123 in
Pf IspF (Figures 3 and 4). These residues are strictly con-
served in IspF. In the E. coli enzyme (EcIspF) Glu135,
helps coordinate either a Mg2+ or Mn2+ together with
the bridging phosphates of the substrate or CDP [19,20].
Although the residue is conserved as Glu137/216
(Figure 4) we do not observe any cation binding here.
In 81% of IspF sequences a glutamate is observed at
this position, and this is conservatively replaced by
aspartate in a further 18%.
The highly conserved histidine and serine combination
(Pf IspF: His115-Ser116, BcIspF: His36-Ser37, identical in
over 96% IspF sequences) located on the loop that leads
to α1, adjacent to the Zn2+ binding site (Figure 2c, d),display elevated B-factors in all structures and in one
chain of the BcIspF:CMP complex the electron density
was of insufficient quality to allow the region to be mod-
elled, indicating a degree of flexibility. Electron density is
absent or poorly defined for the loop linking α2 to α3 in
many of the IspF structures. This segment occurs at one
side of the active site (Asp144 - Asn151 in Pf IspF) and
(Phe63 - Ala73 in BcIspF). This α2 - α3 loop could be
modeled in the BcIspF:2CMP complex although the resi-
dues have elevated B-factors (average 47 Å2), compared
to the average B-value for the entire protein (19 Å2).
The same loop was also modelled for chain A in the
BcIspF-citrate complex. These observations are consist-
ent with the inference that the α2 - α3 loop on one side
of the active site is flexible [16,17].
A hydrophobic cavity occurs at the core of the IspF
trimer. In BcIspF the cavity is lined by the side chains of
Tyr9, Val11, Ile101 and Tyr141, and the floor of the cav-
ity is formed by a ring of six hydrophobic residues, Val3
and Leu155 donated by all three subunits. Similarly in
Pf IspF side chains of Tyr70, Ile72, Ile180 and Val220
line this cavity, and the side chains of Phe230 form the
Figure 3 Structure-based sequence alignment of BcIspF and PfIspF. The alignment has been annotated with elements of secondary
structure. Strictly conserved residues are highlighted in black. Three residues that coordinate Zn2+ are marked with a yellow star. Residues that
bind CDP or CMP 1, are marked with a grey disk and those that bind CMP 2 with an orange triangle. Residues that bind MEcPP in EcIspF [20] are
marked with a magenta triangle. A conserved glutamate that binds either Mg2+ or Mn2+ in EcIspF structures is highlighted with a cyan star. This
figure was prepared using ALINE [29].
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pyrophosphate bind at the entrance to this cavity in sev-
eral IspF structures, for example phosphate is present in
AtIspF [30]. In the structure of BcIspF crystallized with
(NH4)2SO4 as a precipitant, a sulfate is bound by the
side chain of Arg144. In Pf IspF, a sulfate binds close to
this site but dislodged such that anion coordination in-
volves the main chain amides of nearby residues, Val220
from all three subunits, rather than a basic side chain.
When BcIspF is crystallized in the presence of Na2HPO4,
Tyr141 amide groups bind a phosphate in a similar fash-
ion. Isoprenoid-species such as geranyl- or farnesyl-
pyrophosphate have been observed in the central cavity
of some IspF trimers and a possible role in feedback
regulation has been suggested [31-33]. A molecule of di
(hydroxyethyl)ether; a likely decomposition product or
impurity of PEG 3350 used in crystallization, occupies
the cavity in the BcIspF:2CMP structure (Table 2),
possibly mimicking a prenyl chain. A solvated Mg2+
with octahedral coordination is present in the cavity
of the BcIspF:CMP structure forming interactions
similar to those observed in the structure of IspF from
B. pseudomallei [27], data not shown.Complexes with CMP and CDP
Residues from both subunits interact with and position
cytidine nucleotides in the active site. These compounds
constitute fragments of the substrate and provide clues
about aspects of molecular recognition. The structure-
based sequence alignment (Figure 3) and overlay of the
active sites of BcIspF:CMP and Pf IspF:CDP complexes
(Figure 4) indicate that the key enzyme-ligand interac-
tions and aspects of the structure that are implicated in
substrate specificity and the mechanism are highly con-
served. Note that in the Pf IspF:CDP complex two con-
formers of CDP are present that differ in the orientation
of the β-phosphate group. These refined satisfactorily at
occupancy levels of 0.6 and 0.4.
In BcIspF, carbonyl groups from Ala102 and cis-
Pro105 accept hydrogen bonds donated by cytosine N4,
and the amide groups of Leu107 and Ala108 donate
hydrogen bonds to cytosine N3 and O2 respectively. The
ribose O2’ forms a hydrogen bond with Asp58 from the
adjacent subunit while the amide of Gly60, also from the
adjacent subunit, hydrogen bonds to the ribose O3’.
Thr135 amide and side chain hydroxyl groups form
hydrogen bonds to the α-phosphate. Lys134 NZ
Figure 4 Superposition of the active site in BcIspF and Pf IspF.
Residues that bind CMP or CDP are displayed as sticks. Sequence
numbers for BcIspF are followed by those for Pf IspF, and residues
contributed from the adjacent subunit are marked with’. BcIspF and
Pf IspF are colored cyan and green respectively. Key interactions are
detailed in the text.
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ute to catalysis by helping to position the transition-state
intermediate or, in conjunction with Zn2+, to align the
substrate for nucleophilic attack. This interaction in
BcIspF is reminiscent of that previously reported for the
active site Lys132 in Thermus thermophilus IspF [34],
except that in that case the lysine interacts with the
β-phosphate. The side chain of Lys106 is positioned
over the cytosine and contributes van der Waals con-
tacts to stabilize the ligand pose. For clarity this resi-
due is omitted in Figure 4.
We analysed the levels of conservation of these eight
IspF residues detailed as interacting with CMP or CDP.
The residues for which the side chain is key, the glycine
and cis-proline are highly conserved in IspF, at greater
than 95%. Where main chain functional groups are used
the nature of the side chain is less important and the
level of conservation drops to 37% for the equivalent of
Leu107 to 62% for Ala102 in BcIspF. Lys134 is anomal-
ous. This is only lysine in 20% of the sequences and is
more often a threonine, 76% of sequences. Presumably
the reduction in size allows space that a water molecule
could occupy to help facilitate substrate binding.
Surprisingly, a second molecule of CMP was observed
in the active site when BcIspF was co-crystallized in the
presence of 10 mM ligand. This second CMP is likely
due to the high concentration used and represents an
artifact of crystallization, unlikely to have physiological
significance. This new cytidine-binding site is referred to
as position 2 and residues that bind this ligand are from
the same subunit that binds the active site Zn2+, indeed
the CMP 2 phosphate coordinates the metal ion
(Figure 5). The binding of CMP 2 within the three activesites of the asymmetric unit is very similar, for example
the main chain conformation of the α2-α3 loop and the
positions of Leu78 and His36 interacting with van der
Waals forces on either side of the pyrimidine and help-
ing to position it is essentially the same. In addition the
position of Phe63 that helps to position Leu78 is also
conserved. Phe63 is strictly conserved in 96% of IspF se-
quences, Leu78 in 77%. However, there are differences
in the orientation of two side chains that change the de-
tail of the hydrogen bonding interactions with CMP 2.
In active site A (Figure 6) two solvent mediated links are
noted involving the carbonyl groups of Ser64, Phe70 and
Ala73 and cytosine O2 and N3. A direct hydrogen bond
is formed between N4 and the Ala73 carbonyl. The
Phe70 and Ala73 carbonyl groups position a water mol-
ecule that binds cytosine N3 and the Ala73 carbonyl also
interacts directly with cytosine N4. The carboxylate of
Asp65 binds to the ribose O2’. In the other active sites
(not shown), different rotamers of Ser37 place the side
chain OG to accept a hydrogen bond from N4 but for
Asp65 the rotamer orientations results in functional
groups too distant for an interaction with the ribose.
Overlay with the EcIspF-product complex shows that
CMP 2 binds in the same location as MEcPP [20] and
indeed exploits interactions with the same residues, the
majority of which are conserved (Figures 3 and 7). Spe-
cifically, in common with observations regarding recog-
nition of the pyrimidine moiety of substrates we note
that residues that use side chain functional groups to
interact with ligands in the MEcPP binding site are well
conserved, those that use main chain groups less so.
Ser37 is strictly conserved and Asp65 occurs in about
70% of IspF sequences but Ser64, Phe70 and Ala73 are
strictly conserved in 4%, 43% and 58% respectively. The
latter two residues are not conserved in Pf IspF, being re-
placed by asparagine and lysine respectively (Figure 3).
The binding pose of CMP 2 offers clues about molecu-
lar features that might be considered for ligand design
targeting this area of the active site. Potential ligands
could, for example, aim to extend out to recreate the
hydrogen bonding interactions displayed by the two or-
dered water molecules shown in Figure 6. It might also
be useful to test placement of a basic component to
interact with the acidic Asp65.
BcIspF-citrate complex
Attempts to produce unliganded BcIspF crystals for ligand
or fragment soaking experiments initially appeared to be
successful and highly ordered samples were obtained.
However, citrate was present in the best crystallization
conditions and the electron density maps were consistent
with this molecule coordinating the metal ion and there-
fore complicating ligand-binding studies. Two binding
modes were observed. Citrate was well defined in one
Figure 5 Binding pose of two cytidine nucleotides in BcIspF. Hydrogen bonding interactions between BcIspF, water molecules and both
CMP molecules in one active site are depicted with black dashed lines. Residues that contribute to binding interactions only via the main chain
are depicted without side chain atoms. Solvent molecules are depicted as red spheres. Components of one subunit are shown with C atoms
yellow and for the other subunit, cyan. Electron density is displayed for CMP 2 as green chicken-wire corresponding to an |Fo-Fc| map (omit map)
contoured at 2.5 σ.
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less so in the other two where it was modeled with occu-
pancy 0.75 and the average B-factors are approximately 37
and 43 Å2. For comparison, the average B-factor for pro-
tein atoms in this structure is approximately 19 Å2. The
best-defined citrate (Figure 8) binds to the active site Zn2+
via both carboxylate and hydroxyl groups and this is also
observed at one other site. Here the citrate forms
hydrogen-bonding interactions with the main chain am-
ides of His36 and Ser37, and side chains of Asp65 and
Lys134. The interaction involving Asp65 is likely a conse-
quence of the low pH at which crystals were obtained.
Additional solvent mediated interactions to link citrate to
the protein also occur (not shown). The normally flexible
and poorly ordered α2-α3 loop appears to lock down over
the bound citrate adopting a configuration similar to that
observed in the EcIspF-MEcPP complex [20]. In the otherFigure 6 Key residues and interactions to bind CMP 2 in BcIspF.
The color scheme is the same as used in Figure 5.citrate-binding pose (not shown) only a carboxylate coor-
dinates to Zn2+ but hydrogen bonds are also formed
exploiting the same functional groups on the protein, the
amides of His36 and Ser37, Ser37 OG, and Lys134 NZ. It
is clear from these results, that any attempts to investigate
ligand binding at the Zn2+ site will require crystallization
conditions that do not include citrate.
Co-crystallization with potential Zn2+ coordinating ligands
A screen of Zn2+-binding ligands previously identified
L-tryptophan hydroxamate as a ligand for IspF sug-
gesting that the presence of such a group may anchor
ligands in the active site [25]. Subsequent studies with
BpIspF reported a number of metal ion coordinating ligands
[27]. Crystallization trials of Pf IspF and BcIspF in the pres-
ence of several such Zn2+ coordinating ligands (e.g. fosmido-
mycin, benzohydroxamic acid, acetohydroxamic acid and
pyrithione), testing a range of concentrations together with
the absence or presence of CMP were carried out. Citrate
was not present in these crystallization trials. Numerous
datasets have been measured and analyzed but we have not
observed any evidence of selected ligands at the Zn2+ site. In
one case a 2.0 Å resolution dataset was obtained from
BcIspF co-crystallized with 10 mM pyrithione. It quickly be-
came evident that neither Zn2+ nor pyrithione were present
in the structure (not shown) and this suggests that the
ligand may have extracted Zn2+ from the active site.
Conclusions
The structures of IspF from a bacterial (BcIspF) and a
protozoan (Pf IspF) pathogen have been determined and
compared to orthologues. A high degree of structural
Figure 7 CMP 2 occupies the same site as MEcPP. An overlay of
the EcIspF product complex and BcIspF:CMP 2. CMP 2 binds in a
similar site as MEcPP and also coordinates Zn2+. The α2-α3 loop at
one side of the binding site (EcIspF: Phe61-Ser73; BcIspF: Phe63-Ser75)
adopts a different conformation.
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proteins have been assessed for suitability as platforms
for structure-based drug discovery. The cytidine-binding
pocket is relatively rigid in IspF, whereas the pocket that
binds the methylerythritol-phosphate portion of the sub-
strate is relatively flexible. Numerous attempts to obtain
the structure of protein-ligand complexes failed suggest-
ing that the crystallization conditions may need to be
adjusted or alternatives found. We note that in each case
high ionic strength was necessary to obtain well-ordered
crystals. Successful co-crystallization with small mol-
ecule ligands has been reported for EcIspF and BpIspF
[24,25,27] and given the high degree of structural simi-
larity in the IspF active site it might be prudent to use
those enzymes for early stage drug discovery studies.
Previously [26], AtIspF was used as a surrogate for
Pf IspF due to difficulties in working with the later. We
also noted problems with the solubility of Pf IspF and
subsequently identified conditions to circumvent this
issue. However, given the high level of conservation weFigure 8 Citrate binding to Zn2+ in BcIspF. A well-resolved citrate
binds to Zn2+. An omit map is displayed for citrate in green chicken
wire contoured at 3 σ. Residues are shown as sticks and a grey
sphere represents Zn2+. Interactions are marked with dashed lines.
Solvent mediated interactions are not shown.have described then any IspF might be considered a suit-
able surrogate for the apicomplexan enzymes. The unex-
pected observations that a second molecule of CMP can
occupy the active site as well as the presence of citrate
interacting with Zn2+ in BcIspF are noteworthy. These li-
gands provide templates for ligand design addressing




The gene encoding BcIspF was amplified from B. cenoce-
pacia genomic DNA (strain J2315) by PCR using 5′- CAT
ATG GAC TTC AGA ATC GGA CAA GG −3′ and
5′- GGA CCT CAG CCG CCC TGC TTC ACC −3′
as the forward and reverse primers respectively (Thermo
Scientific). The PCR product was ligated into TOPO-
Blunt-II (Invitrogen) then subcloned into a modified
pET15b vector (Novagen), which produces a histidine-
tagged protein with a Tobacco Etch Virus (TEV) protease
site. A single nucleotide error in the forward primer
gave a single amino acid mutation F3V. The gene en-
coding IspF from P. falciparum strain 3D7, [GenBank:
XP_001349603], was synthesized (Genscript) with codons
optimized for recombinant expression in E. coli. The se-
quence encoding residues 1–59, a predicted apicoplast tar-
geting sequence, was excluded and the codon for Cys60
was replaced with one for serine. This synthetic gene was
sub-cloned into the same modified pET15b vector as Bc
ispF. Experimental procedures for recombinant protein
production using E. coli BL-21 (DE3) Gold following pub-
lished methods [19].
Purification of Pf IspF
Pf IspF precipitates at temperatures below 18°C therefore
all procedures were performed at room temperature un-
less otherwise stated. Cells were harvested by centrifuga-
tion at 3000 g for 30 minutes at 18°C and re-suspended
in 100 mM KCl, 100 mM L-arginine, 50 mM CHES,
pH 9.5 (buffer A). DNaseI and a protease inhibitor tablet
(EDTA-free, Roche) were added prior to cell lysis by pas-
sage through a French pressure cell at 16000 psi. Cell
lysate was clarified by ultracentrifugation at 40000 g for
30 minutes at 18°C (Avanti centrifuge, Beckmann) and
the supernatant was syringe filtered (Sartorius).
Lysate was loaded onto a nickel ion affinity chroma-
tography column (5 mL HisTrap HP, GE Healthcare)
using an FPLC system (Äkta Explorer, GE Healthcare).
A linear concentration gradient of imidazole was applied
with elution of Pf IspF occurring at 200 mM mM imid-
azole. The fractions containing IspF were pooled and di-
alyzed against buffer A. The affinity tag (His-tag) was
cleaved with His-tagged TEV protease at 20°C for 16
hours. Protease-treated sample was re-applied to a nickel
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protein eluted. Fractions were analyzed by sodium dode-
cyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and those containing Pf IspF were pooled. The
sample was further purified on a size-exclusion chroma-
tography column (Superdex 200 26/60, GE Healthcare)
equilibrated with buffer A. This column had been cali-
brated with molecular weight standards (Bio-Rad). The
level of Pf IspF purity was confirmed by SDS-PAGE
and matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry. Protein concentration was
estimated spectrophotometrically using a theoretical ex-
tinction coefficient, ε: 11920 M-1 cm-1 at 280 nm, calcu-
lated using ProtParam [35].
Purification of BcIspF
BcIspF was purified in similar fashion to Pf IspF except
that a different buffer, (100 mM NaCl, 100 mM Tris–
HCl, pH 7.5, buffer B) was used. Removal of the His-tag
reduced the solubility of the protein significantly. Once
this problem was identified the tag was left in place. The
temperature sensitivity observed for Pf IspF was not seen
for BcIspF and samples were kept either on ice or at 4°C
throughout. BcIspF concentration was measured using
the Bradford assay (Thermo Scientific).
Screening for crystallization conditions
An automated liquid-handling system (Phoenix, Art
Robbins) was used for screening crystallization conditions
in combination with commercially available screens. All
samples were filtered through a 0.1 μm PVDF filter
(Ultrafree, Millipore) immediately prior to screening.
Sitting-drops were formed by mixing 100 nL sample
with either 100 or 200 nL of reservoir. Reservoir volumes
were 60 μl. Conditions identified from the screens were
subsequently scaled up and optimized.
Crystallization of a Pf IspF:CDP complex and unliganded
Pf IspF
Pf IspF was concentrated to 6 mg mL-1 using a 10 kDa
cutoff centrifugal filter (Vivaspin 20, Sartorius) to pro-
vide a stock solution for crystallization. The sample was
supplemented with MgCl2 (2 mM) and CDP disodium
salt (2 mM, Sigma-Aldrich). Hanging drops were pre-
pared consisting of 2 μl sample mixed with 2 μl of reser-
voir (1.8-2.5 M (NH4)2SO4, 5 mM ZnCl2 and 100 mM
Bis-Tris, pH 5.5). Diffusion against 1000 μl of reservoir
led to the formation of small prismatic crystals (approxi-
mate dimensions 0.15 × 0.15 × 0.15 mm) within 2–4
days. Isomorphous crystals were also obtained with
10 mM fosmidomycin present in the crystallization drop.
Crystals were transferred to drops containing saturated
sucrose solution, for ~5 seconds before flash cooling in
liquid nitrogen.Crystallization of BcIspF complexes
BcIspF was concentrated to 5 mg mL-1 in buffer B, simi-
lar to Pf IspF and the solution adjusted to include 2 mM
MgCl2 and 20 mM CMP disodium salt (Sigma-Aldrich).
A second sample was prepared at 10 mg mL-1 in buffer
C (100 mM NaCl, 2 mM MgCl2, 100 mM sodium for-
mate, pH 5.0) to which CMP (2 mM) was also added.
The BcIspF CMP 2 structure was obtained from crys-
tals grown by mixing 2 μL of the sample in buffer B with
reservoir (2 μL) containing 25% w/v PEG 3350, 2.2 M
(NH4)2SO4, 0.1 M sodium formate, pH 5.0, and 1% v/v
dioxane. Orthorhombic blocks reached maximum size
within ten days. A crystal of approximate dimensions
0.15 × 0.10 × 0.10 mm was used for data collection. Buf-
fer B supplemented with 20% v/v glycerol was used as a
cryoprotectant.
The second sample gave the BcIspF CMP structure.
This was crystallized by mixing 2 μL with 4 μL reservoir
containing 5% w/v PEG 1000, 33% v/v ethanol, 0.1 M
Na2HPO4, pH 4.0, and 2% v/v dioxane. A crystal of ap-
proximate dimensions 0.25 × 0.10 × 0.10 mm grew over
six days and was used for data collection. A mixture of
buffer C with reservoir (1:2), replacing PEG 1000 with
PEG 4000 at 25% w/v, was used as a cryoprotectant.
The BcIspF:citrate structure was derived from protein
concentrated to 10 mg mL-1 in buffer D (100 mM NaCl,
100 mM sodium formate, pH 5.0), and crystallized by
mixing (1.5 μL) with a reservoir (3 μL) containing 5% w/
v PEG 1000, 36% v/v ethanol, 0.1 M Na2HPO4 and
0.1 M citric acid, pH 4.2. A different crystal form to that
previously found, grew within 4 days to approximate di-
mensions 0.4 × 0.1 × 0.1 mm. A mixture of sample buf-
fer with reservoir (1:2), replacing PEG 1000 with PEG
4000 at 25% w/v, was used as a cryoprotectant. Datasets
for the BcIspF complex crystals were collected on the in-
house X-ray system as described for Pf IspF.
Crystals were screened in-house using a rotating-anode
X-ray source (MicroMax 007 HF, Rigaku) equipped with a
dual image plate detector (RAXIS IV++). Diffraction data
from the Pf IspF:CDP complex were collected on beamline
ID29 at the European Synchrotron Radiation Facility
(ESRF, Grenoble) at −170°C using an ADSC Quantum
315r CCD detector. Data from the crystals grown in the
presence of fosmidomycin were collected in-house. Subse-
quently it was determined that fosmidomycin was not or-
dered and this is therefore considered to be an unliganded
Pf IspF structure. Datasets for the BcIspF complex crystals
were all collected on the in-house X-ray system described
above.
Data processing, structure solution and refinement
Diffraction data were indexed and integrated using
MOSFLM [36] or XDS [37] and scaled with SCALA [38]
with 5% of data flagged for Rfree calculations. The Rfree
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structures were solved by molecular replacement using
PHASER [39]. Different search models, edited to remove
all non-protein atoms, were used for these calculations.
The coordinates of E. coli IspF [PDB:1GX1] with ~33%
sequence identity, [19] and B. pseudomallei [PDB:3F0G]
63% identity, [27] were used to determine the Pf IspF:
CDP and BcIspF:2CMP structures respectively. B-factors
of the replacement models were adjusted to match the
Wilson B-factor derived from scaling of the data. Subse-
quently these parent structures were used as the starting
points for analyses of the other structures. Crystals of
Pf IspF display differing degrees of twinning as recog-
nised in SCALA and a twin fraction of 0.14 was applied
to the CDP complex.
Refinement calculations were performed with REFMAC5
[40] and the resulting models together with electron dens-
ity and difference density maps were inspected in COOT,
which also allowed for model adjustment to improve the
fit to density [41]. Water molecules, ions, ligands and con-
formational rotamers were added to the models as the re-
finements progressed. In the case of citrate molecules
binding to BcIspF, one site was well ordered but the other
two sites displayed more diffuse electron density and a de-
cision was taken to set the occupancy to 0.75. These then
refined satisfactorily with no residual features in the result-
ing difference density maps. Strict NCS restraints were
employed in the early stages of refinement and then re-
moved towards the latter stages. To confirm the presence
of ligand molecules in the final models, |Fo-Fc| electron
density difference maps, referred to as ‘omit maps’, were
prepared by excluding ligands from Fc calculation, several
cycles of refinment in REFMAC5 and inspection of the
maps in COOT. The validation tools in COOT and the
MolProbity server [42] were used to assess model geom-
etry. Comparisons with structures in the PDB were per-
formed using the DALI server [28]. The Protein Interfaces,
Surfaces & Assemblies server, [43] was used to calculate
surface and interface areas and figures were prepared with
PyMOL [44].
Sequence analyses
A search in UniProt for IspF sequences using the E.C.
number [4.6.1.12] returned 2458 entries. The list was fil-
tered down to 2229 by excluding the bifunctional IspDF
examples and fragmentary protein sequences. Sequences
with greater than or equal to 90% identity were clustered
and a single representative sequence identified for each
cluster, reducing the list to 876 sequences. These were
inspected and a decision taken to remove a number of
sequences that still appeared to be fragmentary. A final
set of 854 IspF sequences were submitted to the European
Bioinformatics Institute-ClustalOmega multiple sequence
alignment server [45]. The alignment was displayed inJalview [46] and percentage conservation scores were
manually calculated for all residues marked in Figure 3.
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